These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35274955)

  • 1. Opalescence Arising from Network Assembly in Antibody Solution.
    Nakauchi Y; Nishinami S; Murakami Y; Ogura T; Kano H; Shiraki K
    Mol Pharm; 2022 Apr; 19(4):1160-1167. PubMed ID: 35274955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine suppresses opalescence and liquid-liquid phase separation in IgG solutions.
    Oki S; Nishinami S; Shiraki K
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1708-1712. PubMed ID: 29981328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine and its Derivatives Suppress the Opalescence of an Antibody Solution.
    Oki S; Nishinami S; Nakauchi Y; Ogura T; Shiraki K
    J Pharm Sci; 2022 Apr; 111(4):1126-1132. PubMed ID: 34843741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical Perspective on Opalescence and Liquid-Liquid Phase Separation in Protein Solutions.
    Raut AS; Kalonia DS
    Mol Pharm; 2016 May; 13(5):1431-44. PubMed ID: 27017836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opalescence in monoclonal antibody solutions and its correlation with intermolecular interactions in dilute and concentrated solutions.
    Raut AS; Kalonia DS
    J Pharm Sci; 2015 Apr; 104(4):1263-74. PubMed ID: 25556561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimerization Dictates Solution Opalescence of a Monoclonal Antibody.
    Yang TC; Langford AJ; Kumar S; Ruesch JC; Wang W
    J Pharm Sci; 2016 Aug; 105(8):2328-37. PubMed ID: 27373839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Opalescence in low Volume Monoclonal Antibody Solutions Enabled by Microscale Nephelometry.
    Kingsbury JS; Lantz MM; Saini A; Wang MZ; Gokarn YR
    J Pharm Sci; 2021 Sep; 110(9):3176-3182. PubMed ID: 34004217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations.
    Inoue N; Takai E; Arakawa T; Shiraki K
    Mol Pharm; 2014 Jun; 11(6):1889-96. PubMed ID: 24689736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation.
    Mason BD; Zhang L; Remmele RL; Zhang J
    J Pharm Sci; 2011 Nov; 100(11):4587-96. PubMed ID: 21638285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid-Liquid Phase Separation in a Dual Variable Domain Immunoglobulin Protein Solution: Effect of Formulation Factors and Protein-Protein Interactions.
    Raut AS; Kalonia DS
    Mol Pharm; 2015 Sep; 12(9):3261-71. PubMed ID: 26237070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermal aggregation of human immunoglobulin G in arginine solutions: Contrasting effects of stabilizers and destabilizers.
    Yoshizawa S; Arakawa T; Shiraki K
    Int J Biol Macromol; 2017 Nov; 104(Pt A):650-655. PubMed ID: 28647523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opalescence Measurements: Improvements in Fundamental Knowledge, Identifying Sources of Analytical Biases, and Advanced Applications for the Development of Therapeutic Proteins.
    Barros M; Zhang X; Kenrick S; Valente JJ
    J Pharm Sci; 2021 Nov; 110(11):3550-3557. PubMed ID: 34111445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.
    Bahrenburg S; Karow AR; Garidel P
    Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of translucency and opalescence among different dental monolithic ceramics.
    Shirani M; Savabi O; Mosharraf R; Akhavankhaleghi M; Hebibkhodaei M; Isler S
    J Prosthet Dent; 2021 Sep; 126(3):446.e1-446.e6. PubMed ID: 34304886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding opalescence measurements of biologics - A comparison study of methods, standards, and molecules.
    Kunz P; Stuckenberger E; Hausmann K; Gentiluomo L; Neustrup M; Michalakis S; Rieser R; Romeijn S; Wichmann C; Windisch R; Hawe A; Jiskoot W; Menzen T
    Int J Pharm; 2022 Nov; 628():122321. PubMed ID: 36273703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ceramic thickness on opalescence.
    Valizadeh S; Mahmoudi Nahavandi A; Daryadar M; Özcan M; Hashemikamangar SS
    Clin Exp Dent Res; 2020 Dec; 6(6):693-699. PubMed ID: 32902165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compendial Methods: Suitability Verification, Challenges and Recommendations for Proteins.
    Chung WL; Yin J; Messick S; Saggu M; Tschudi K; Woys A; Rahimi R; Azarias M; Kong C; Kabakoff B
    PDA J Pharm Sci Technol; 2020; 74(5):581-591. PubMed ID: 32295862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
    Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
    Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of PEG-induced precipitation with protein-protein interactions and aggregation rates of high concentration mAb formulations at 5 °C.
    Wälchli R; Fanizzi F; Massant J; Arosio P
    Eur J Pharm Biopharm; 2020 Jun; 151():53-60. PubMed ID: 32197816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.